Severe sepsis is a syndrome of systemic inflammation in response to infection that results in multi-organ dysfunction, shock, and death in 20-50% of patients 1 . While inflammation is central to the pathogenesis of sepsis, many other biological systems conspire to produce pathology in this disease 2 . Notably, collaboration between the innate immune system and the hemostatic system (platelets and coagulation factors) has been identified as a principle offender in the pathogenesis of sepsis. Progressive thromobocytopenia and coagulopathy are strong negative prognostic findings in severe sepsis, and have recently been included in the updated definition of the disease 3 . The extreme phenotype of pathological coagulation in sepsis is the development of disseminated intravascular coagulation (DIC), a devastating syndrome of systemic microvascular thrombosis and coagulation with a high mortality rate, for which there is no specific treatment 4 . Understanding the cellular and molecular mechanisms that promote the development of pathological coagulation in sepsis may provide targets for therapeutic development, and yield insight into the collaboration between innate immunity and coagulation in health and disease.
Neutrophils are central to the inflammatory pathogenesis of sepsis, and a number of components of the neutrophil armamentarium are known to interact with coagulation factors and platelets [5] [6] [7] . In particular, recent evidence has implicated neutrophil extracellular traps (NETs) in the activation of platelets and coagulation in vitro, as well as in models of deep vein thrombosis in vivo 8, 9 . Individually, various components of NETs have been identified as initiators or propagators of coagulation activity, including proteolytic constituents and histones 7, 10 . Aggregation of platelets within the
microvasculature during Gram-negative bacterial sepsis is largely neutrophil-dependent, and is linked to the release of NETs 5, 6, 11 . Furthermore, electron microscopy of NETs formed in vitro has shown that platelets can bind directly to NETs 9 . During sepsis, neutrophils cast NETs throughout the microcirculation of multiple organs, where they participate in host defense by capturing circulating bacteria, but also contribute to the development of end-organ damage 6, 12 . However, the role of NETs (and their interactions with platelets and coagulation factors in vivo) in the development of sepsis-induced intravascular coagulation has not been comprehensively investigated.
Previous research on coagulation in sepsis has relied primarily on peripheral blood samples and ex vivo assays of coagulation, but understanding the dynamics of coagulation and interactions with the immune system in vivo require that this process be studied at the site of action, within the tissue microvasculature. Advancements in intravital imaging now enable multi-color visualization of complex biological processes within the microcirculation. Furthermore, intravital microscopy enables a better understanding of how infection-induced coagulation directly impacts microvascular perfusion in the live animal. Herein, using high-resolution confocal intravital microscopy, we demonstrate that collaboration between NETs, platelets, and the release of inorganic polyphosphate promotes disseminated activation of the coagulation system within the microvasculature during sepsis, independent of the inciting pathogen (Gramnegative, Gram-positive, or pure bacterial product). Dynamic perfusion imaging revealed that NETs-induced intravascular coagulation caused widespread microvasculature occlusion, ultimately leading to end-organ damage, which is prevented by inhibiting or dismantling NETs. Together, our data reveal a NETs-platelets-thrombin axis that is
fundamental to the development of microvascular dysfunction and organ damage in sepsis.
Methods

Mice
C57Bl/6J mice were purchased from Jackson Laboratories (Bar Harbor, Maine). PAD4-deficient mice (PAD4-/-) on a C57Bl/6J background were a gift from the late Dr. Kerri
Mowen (Scripps Research Institute, La Jolla, Ca). Animals were maintained in a pathogen-free environment at the University of Calgary Animal Resource Centre. All experimental animal protocols were approved by the University of Calgary Animal Care
Committee and were in compliance with guidelines from the Canadian Council for Animal
Care (Protocol AC14-0056).
Antibodies and Reagents
The following antibodies and reagents were used: DNase I (Roche), argatroban (Sigma), AF660-labeled anti-Gr1 (eBioscience), AF647-labeled anti-mouse CD49b (Biolegend), goat anti-mouse histone H2Ax (Santa Cruz Biotechnology), sheep anti-human (with mouse cross-reactivity) fibrin/fibrinogen IgG (AbD Serotec). Unconjugated antibodies used for fluorescence imaging were labeled with Alexa-fluor protein labeling kits according to the manufacturer's instructions (Thermo Fischer Scientific). Fluorescent thrombin substrate used for in vivo imaging analysis (SensoLyte internally quenched 5-FAM/QXL-520 FRET thrombin substrate) was purchased from Anaspec. Monoclonal antibodies against histone H4 (MHIS1952) and polyphosphate (PP2055) were developed in the Esmon laboratory as described previously 13 .
Intravital Microscopy
The protocol for intravital imaging were performed as previously described 14 . Specific details of specifications of spinning disk intravital microscope and resonance scanning confocal intravital microscope are provided in supplemental methods.
Image Analysis
NET components were visualized using AF555-anti-H2Ax antibody (5 μg/mouse), and in some experiments, AF647-anti-neutrophil elastase (0.6 μg/mouse), and Sytox green DNA stain (10 μL of 50 pM solution/mouse). Platelets were visualized using AF647-anti- 
infection experiments, bacteria (USA300-2406) were grown to mid-log phase in BHIchloramphenicol broth, washed, re-suspended in saline, and injected i.v. (2x10 7 CFU).
ELISA and Biochemical Assays
Plasma was obtained in the usual fashion from whole blood collected from anesthetized mice via cardiac puncture. A commercially available ELISA kit was used to measure levels of thrombin-antithrombin complexes (Abcam), and plasminogen activator inhibitor-1 (PAI-1) (Molecular Innovations). Commercially available colorometric assays were used to measure plasma levels of ALT, creatinine, and lactate (Sigma).
Statistical Analysis
All data are presented as mean values ± SEM. A student's t-test (for parametric data) or
Mann-Whittney U test (for non-parametric data) was used to determine the significance between population means when two groups were compared. When more than two groups were compared, a one-way analysis of variance with post-hoc Bonferroni test was used for multiple comparisons. Statistical significance was set at P<0.05.
Results
Intravascular coagulation and thrombosis in the liver microcirculation during sepsis.
Using multichannel spinning-disk confocal intravital microscopy (SD-IVM) or resonance-scanning confocal intravital microscopy (RS-IVM), the liver microcirculation was visualized in untreated control mice ( Figure Together with the disseminated activation of intravascular thrombin, we also observed profound aggregation of platelets in the liver microcirculation in response to endotoxemia, E. coli, and S. aureaus ( Figure 1E , G-H). In contrast, within the livers of untreated control mice, platelets flowed freely through the microvasculature, occasionally
undergoing transient touch-and-go interactions with the endothelium, but not forming any durable aggregates ( Figure 1B ). This is in keeping with previous observations of extensive intravascular platelet aggregation within liver sinusoids during sepsis 6, 11 .
NETs promote intravascular coagulation during sepsis.
To test the hypothesis that the activation of intravascular coagulation is related to the presence of NETs, we visualized the spatial relationship between these processes within the liver microcirculation ( Figure 2 ). NETs were identified as extracellular structures composed of DNA, histones, and neutrophil proteins (such as neutrophil elastase), and
were quantified based on histone H2Ax, as previously described Similarly, visualization of terminal product of coagulation, fibrin, demonstrated colocalization with NETs ( Fig S4) . It should be noted that this fluorescent thrombin substrate is soluble, and as such can dissipate from its site of activation. Analysis of the location of maximal thrombin signal within each vessel in relation to the closest NET revealed that 71.2% of thrombin activity was within or immediately downstream of NETs, whereas only 12.6% was observed upstream of NETs, and 16.2% was not associated with NETs (>100 μm from the nearest NET) ( Figure 2C ). Together, these
data demonstrate that the majority of intravascular thrombin is found within or immediately downstream of NETs.
Having identified a clear spatial relationship between intravascular coagulation and NETs, we aimed to investigate the functional relationship between these processes through the inhibition of NETs production using peptidylarginine deiminase-4 (PAD4 To control for the possibility that PAD4-deficient mice have an intrinsic defect in coagulation, we utilized a second experimental approach to investigate the effect of NETs inhibition on intravascular coagulation. In these experiments, septic mice (LPS, E. coli, or S. aureus) were treated with intravenous (i.v.) DNase to dismantle the structure of NETs ( Figure S5A -C), as previously described 6, 16, 21 . Indeed, treatment with i.v. DNase significantly reduced intravascular thrombin activity compared to control-treated animals (Fig S5D-F) . The low level of thrombin activity in PAD4-deficient mice was unchanged when PAD4-deficient mice were administered i.v. DNase ( Figure S6A-D) .
Minor contribution of NETs to microvascular platelet aggregation
Platelets are critical to effective hemostasis and contribute to the generation of pathological coagulation in a variety of diseases, but are also essential for the release of
NETs by neutrophils during Gram-negative sepsis 5 . Given that platelets contribute to both coagulation and NETs function, we sought to investigate the interaction between platelets, NETs, and intravascular coagulation in sepsis. First, visualization of the platelet response within the microvasculature of septic mice revealed profound aggregation within sinusoids ( Figure 4A ). The majority of platelets were observed to aggregate upon the surface of neutrophils, undergoing dynamic adhesion and aggregation ( Figure 4B , and Video 4). We have previously shown that platelet aggregation on the surface of neutrophils is dependent on the adhesion molecule LFA-1 6 . However, some platelets were observed to adhere within the vasculature remote from neutrophils, within areas of NETs ( Figure 4C ). Furthermore, a small but significant reduction in the quantity of adherent platelets was observed in PAD4-deficient mice, despite no difference in the number of adherent neutrophils ( Figure 4D , and Figure S7A ). The number of circulating platelets was unchanged by the dismantling NETs with i.v. DNase ( Figure S7B ), again suggesting only a minor contribution of platelet-NETs interaction to the systemic consumption of platelets. Platelet aggregation is pathogen-independent, as E. coli and S.
aureus failed to induce platelet aggregation in vitro (data not shown). These data suggest that the majority of the microvascular platelet aggregation that occurs in sepsis is the result of platelet-neutrophil interactions, whereas only a minority of platelets (~30% or less) undergo direct platelet-NET binding in the microvasculature.
Histone H4 and inorganic polyphosphate promote intravascular coagulation, but not platelet sequestration or NETs production.
Histone H4 contributes to organ damage and mortality when released into the extracellular environment in bacterial sepsis 13 . In addition, in vitro studies have demonstrated that histone proteins can activate the coagulation cascade via a number of mechanisms 10, 22 . Given that NETs are a major source of extracellular histones during sepsis, we hypothesized that extracellular histones, specifically H4, contribute to the activation of intravascular coagulation in sepsis. To test this hypothesis, LPS-treated mice were administered a monoclonal H4-blocking antibody (MHIS1952), or isotypecontrol IgG, and the quantity of intravascular thrombin activity was measured ( Figure 5 ).
Mice receiving control IgG demonstrated diffuse intravascular thrombin activity, whereas treatment with H4-blocking antibody dramatically inhibited the amount of active thrombin observed within liver sinusoids ( Figure 5A-B) . Furthermore, quantification of thrombin probe fluorescence confirmed a marked reduction in the quantity of intravascular thrombin activity in anti-H4-treated mice compared to control-treated mice ( Figure 5C ). Notably, neutralization of histone H4 did not affect the quantity of NETs ( Figure 5D ), nor platelet adhesion within the vasculature ( Figure 5E ).
Semeraro and colleagues have suggested that histone H4 contributes to activation of the coagulation cascade through a mechanism involving inorganic polyphosphate (PolyP)
release from platelets 10 . To test this hypothesis in vivo, septic mice were treated with a monoclonal blocking antibody against inorganic-PolyP. Indeed, neutralization of
polyphosphate significantly reduced intravascular thrombin activity, without affecting the quantity of NETs, or platelets within the microvasculature ( Figure 5F -H). Furthermore, others have suggested the extracellular histones may contribute to coagulation through augmentation of tissue factor expression. We observed increased levels of tissue factor within the microvasculature of septic mice within areas of NETs and thrombin activity ( Figure S8 ). Together, our in vivo data would support previous in vitro findings of a key collaboration between histone H4 in NETs, platelets, and inorganic polyphosphate, and possibly tissue factor in the development of disseminated intravascular coagulation in sepsis.
Blocking NETs-induced intravascular coagulation restores microvascular perfusion in sepsis.
Microvascular hypoperfusion is a key pathologic feature of severe sepsis and septic shock 23 . While this phenomenon can be difficult to assess clinically, the use of intravital microscopy allows us to directly assess microvascular perfusion in live animals in realtime. Using a fluorescent contrast dye (AF647-labeled albumin), we investigated the perfusion of liver sinusoids in relation to intravascular thrombin activity. We observed that ~50% of sinusoids were occluded in septic mice, and that indeed, occluded vessels were those that contained high amounts of active thrombin ( Figure 6A-B) . Furthermore, the reduction in intravascular thrombin activity observed in PAD4-deficient mice ( Figure   6C -E) or mice treated with i.v. DNase ( Figure 6F ) resulted in significantly reduced microvascular occlusion compared to control animals. Similarly, inhibiting NETs-
mediated intravascular coagulation by treating septic mice with i.v. DNase resulted in significantly lower levels of serum lactate compared to control animals ( Figure 6G ).
Together, these data support the conclusion that NETs-induced intravascular coagulation is a fundamental contributor to microvascular hypoperfusion in sepsis.
Inhibition of NETs attenuates intravascular coagulation and end-organ damage in bacterial sepsis.
To determine if our observations within the liver microvasculature were also occurring within other organs, we performed in vivo imaging of the microvasculature in the lungs ( Figure 7A ), spleen ( Figure S9A ), and mesentery ( Figure S9B ). Indeed, similar to the hepatic microvasculature, we observed the co-localization of NETs and intravascular thrombin activity ( Figure 7A and Figure S9 ). To investigate the role of NETs in intravascular coagulation and end-organ damage on a systemic level, septic wild-type control and PAD4-deficient mice were evaluated for systemic markers of intravascular coagulation (intravascular thrombin activity within the lungs and liver, plasma TAT levels, and plasma PAI-1 levels) as well as biomarkers of organ dysfunction (ALT and creatinine) were quantified. Compared to wild-type controls, PAD4-deficient mice displayed significantly reduced levels of intravascular thrombin activity, TAT, and PAI-1 ( Figure 7B-E) . Furthermore, PAD4-deficiency also markedly attenuated end-organ damage compared to wild-type controls, with a 59% reduction in serum ALT, and a 45% reduction in creatinine ( Figure 7F-G) . Taken together, these results indicate that NETs
are key pathological mediators in systemic intravascular coagulation and subsequent endorgan damage in bacterial sepsis.
Given that NETs are complex structures composed of multiple potential pathological mediators 24 , it is possible that the diminished end-organ damage observed in PAD4-deficient mice is the result of multiple factors in addition to reduced intravascular coagulation. To investigate this possibility, we aimed to elucidate the contribution of coagulation alone to end-organ damage in sepsis. Septic mice were treated with the direct thrombin inhibitor argatroban to block intravascular coagulation (see Figure 1 above). As anticipated, direct inhibition of thrombin with argatroban significantly reduced markers of intravascular coagulation ( Figure S10A-B) . However, no significant changes in serum ALT or creatinine were observed in argatroban-treated animals compared to controls ( Figure S10C-D) . Together, these data suggest that inhibition of NETs disrupts both intravascular coagulation and organ damage, whereas anticoagulation alone does not significantly impact organ pathology in Gram-negative sepsis. 25, 26 . Furthermore, studies of NETs within arterial thrombi of humans have identified tissue factor within the structure of NETs, which is consistent with our observations within the liver microvasculature, suggesting a direct link between NETs and the extrinsic-pathway of coagulation 27 . In addition, extracellular histones within NETs can precipitate coagulation in a pleiotropic fashion; via the contact-pathway, tissue factor upregulation, as well as indirectly via platelet activation 10, 28 . Our results extend this to the stetting of sepsis-induced coagulation, as neutralization of histone H4 within
NETs dramatically attenuated intravascular coagulation and microvascular dysfunction.
Furthermore, our data suggest that the structural integrity of NETs is critical to their ability to promote coagulation, given that destruction of the DNA backbone with i. Our findings also expand the previously underappreciated role of platelets in the pathophysiology of sepsis and intravascular coagulation. Platelets are critical to the production of NETs during Gram-negative sepsis, through their ability to bind to neutrophils and induce NET release 5, 6, 29 . In doing so, platelets form aggregates on the surface of neutrophils, resulting in their sequestration within the microvasculature and the development of sepsis-induced thrombocytopenia 5, 6 . Though platelet-neutrophil interactions account for the vast majority of microvascular platelet consumption, some of the sequestered platelets were observed to bind directly to NETs, consistent with previous observations from models of venous thrombosis 9 . Multiple components of NETs are
known to activate platelets, including DNA, multiple histone proteins (in a redundant manner), and neutrophil proteases (via PARs) 30, 31 . Together, these findings suggest a vicious cycle of microvascular thrombosis, wherein platelets accumulate on the surface of neutrophils, and in doing so activate NETs release, which then precipitates further platelet aggregation directly. This dramatic formation of platelets-neutrophil-NET macrostructures within the vasculature fuels the activation and propagation of intravascular coagulation. Recently, inorganic polyphosphate (released from the dense granules of platelets) has been implicated as a potent activator of thrombin, primarily via the contact-pathway through FXII activation 32 . In fact, a primary mechanism by which histone H4 activates thrombin in vitro is via stimulation of inorganic polyphosphate release from platelets 10 . Indeed, we observed a significant reduction in intravascular thrombin activity after neutralization of inorganic polyphosphate, implicating this molecule as a keystone of the platelets-NETs-coagulation axis. Further refinement of the cellular and molecular interactions that support this axis represents an important avenue for future research, and may yield new targets for the development of anticoagulants.
Lastly, our findings add to a growing body of literature highlighting NETs as a potential therapeutic target in sepsis, with our data suggesting a potential role for NETs inhibition in the treatment of disseminated intravascular coagulation. Small cohort studies of patients admitted to the ICU with septic shock have found that increasing levels of circulating NETs biomarkers (free DNA/MPO complexes) correlate with disease severity scores (SOFA) and multi-organ dysfunction 33 . Animal models of severe bacterial sepsis have found that treatment with intravenous DNase decreases end-organ damage, and improves survival 6, 20, 33, 34 . Our data not only replicate these observations, but also extend
them to provide further insight into the mechanisms by which targeting NETs may be of therapeutic benefit. We observed that inhibiting NETs drastically improved perfusion through liver sinusoids, and on a systemic level, reduced serum lactate levels. In fact, we found that treatment with i.v. DNase reduced lactate levels by ~50% in septic animals without fluid resuscitation or antibiotics. Interestingly, while targeting NETs yielded significant attenuation of end-organ damage, treatment with a direct thrombin inhibitor (argatroban) did not. Indeed, NETs pose additional threats to host cells beyond their ability to activate coagulation, including the fact that multiple components of NETs can be directly cytotoxic to host cells 24 . As our understanding of the biology of NETs production expands, further strategies to disrupt this pathological axis will be revealed. 
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Figure Legends Plasma TAT levels were quantified in PAD4+/+ and PAD4-/-mice 6 hours after i.v. S.
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